Soleno Therapeutics has achieved a significant milestone in the treatment of a rare genetic disorder, announcing the publication of pivotal clinical study results for VYKAT™
Editor’s Note: Patient Worthy is proud to share this caregiver story submitted to us by Missy Williams. Nine years later, I can still picture the
ImmunityBio’s latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with
Editor’s Note: Patient Worthy is proud to share this article, originally written by Katie Tat, from our friends at Elephants & Tea. To see the
As reported on Science Daily, a recent clinical study suggests that a traditional Chinese herbal remedy may offer a unique advantage in treating major depressive
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to
Editor’s Note: Patient Worthy is honored to share Michelle Patidar’s patient story, provided to us by our friends at Elephants & Tea. To see the
My chronic health journey is super complicated. When I first started experiencing my symptoms I wouldn’t tell anyone what I was feeling. I would wake
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet,
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH),
CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic
As reported on PharmaBiz, Amneal Pharmaceuticals, in collaboration with mAbxience, has received U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars: Boncresa (referencing
As reported on Science Daily, a groundbreaking study suggests that customizing breast cancer screening based on individual risk factors may outperform the traditional one-size-fits-all approach
Coya Therapeutics has achieved an important regulatory milestone with U.S. FDA acceptance of an Investigational New Drug (IND) application for COYA 302, marking the advancement
In a recent statement, the U.S. Food and Drug Administration (FDA) has authorized regular approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer
A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According
Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard
Researchers at Oregon Health & Science University have made a significant breakthrough in the fight against acute myeloid leukaemia (AML), discovering that combining a standard
From our Friends International Rett Syndrome FoundationIt's TIME! Registration is officially open for both the ASCEND 2026 Rett Syndrome National Summit and the annual Scientific Meeting!
Over 5 impactful days, parents, families, clinicians, researchers, and Rett organizations from around the world will connect, learn, and drive progress—together. This summer, we're excited to head to the Mystic Lake Center & Hotel, located in beautiful Prior Lake, 25 minutes outside the Twin Cities. We can't wait to see you there!💜
Lock in early bird pricing by registering by April 17th. For event information, registration, room blocks, FAQs, and more:
Scientific Meeting 🔗: www.rettsyndrome.org/researchers/annual-rett-syndrome-scientific-meeting/
ASCEND 🔗: www.rettsyndrome.org/families/rett-education/ascend-national-summit/
@Haley's Hope #Pompe #disabled
·
🚐♿ This space isn’t extra — it’s access.
The striped area next to my van isn’t there by accident. It’s where my wheelchair ramp needs to deploy so I can get in and out.
When someone parks even a few inches over that line, I may not be able to access my van at all — not because of my wheelchair, but because the access space is blocked.
When I’m riding with others, we can usually make it work. But as I look toward driving independently, that won’t be possible if this space isn’t kept clear.
I truly believe most people don’t realize this, but It’s not about blame — it’s about awareness. A small parking adjustment can be the difference between independence and being completely stuck.
Please help spread the word. Awareness creates access.
What's next after symptoms? 🧐 Learn more about the diagnostic journey for IgA Nephropathy. Click the link to share your story: bit.ly/3VuxFDV
#igan #kidneyhealth #renalhealth #PatientWorthy 💉
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
